Difference between revisions of "Tranylcypromine-bupropion"

From Psychiatrienet
Jump to: navigation, search
 
(One intermediate revision by one other user not shown)
Line 5: Line 5:
 
{{stopTranyl}}
 
{{stopTranyl}}
 
| start =   
 
| start =   
* '''Day 2:''' start administration of bupropion in a dosage of 150 mg/day.  
+
* '''Day 10:''' start administration of bupropion in a dosage of 150 mg/day and gradually increase dose as necessary.  
 
| info =  
 
| info =  
 
{{Tcrestore}}<ref name="informatorium">{{KNMP|tranylcypromine}}</ref>
 
{{Tcrestore}}<ref name="informatorium">{{KNMP|tranylcypromine}}</ref>
 +
* Tranylcypromine has to be phased out to avoid withdrawal symptoms.<ref>Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers</ref>
 
}}
 
}}

Latest revision as of 16:26, 30 June 2023

Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine
Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion

Switch medication from tranylcypromine to bupropion.[1] [2]

Nietinrijdenbord.png Stop tranylcypromine
  • Day 1: decrease the original dose with about 25% every 3 days.
  • Day 9: stop administration of tranylcypromine.
Eenrichtingbord.png Start bupropion
  • Day 10: start administration of bupropion in a dosage of 150 mg/day and gradually increase dose as necessary.
Infobord.png More information
  • After the last dose of tranylcypromine it takes about 14 days to restore the activity of the MAO enzymes[3]
  • Tranylcypromine has to be phased out to avoid withdrawal symptoms.[4]
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. KNMP; Informatorium Medicamentorum 2023; Monografie "tranylcypromine" (Dutch)
  4. Dr. M.J.Blom et al. (2009) Gebruik van klassieke MAO-remmers
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.